Truist Securities Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $45
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $48 to $45.
Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $48 to $45.